• 出版社/出版日：Mordor Intelligence / 2021年2月25日
|Single User||￥480,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥536,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥847,500 (USD7,500)||▷ お問い合わせ|
The Next-generation Sequencing market was valued at about USD 7,580 million in 2020 and is expected to reach approximately USD 18,550 million in 2026, by registering a CAGR of nearly 19.1% over the forecast period.
Next-generation sequencing (NGS) diagnostic technology has the potential advantage of determining the genetic sequence of a virus and helping scientists understand the mutation of the virus. Throughout the COVID-19 pandemic, government authorities across the world are constantly working with the private sector to bring NGS technology as the potential diagnostic tool in the market. In June 2020, the United States Food and Drug Administration (US FDA) issued an emergency use authorization (EUA) to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA.
The major factors, such as increasing research and development activities utilizing the NGS technologies, growing applications of NGS in clinical diagnosis, and discovery applications demanding NGS technology are expected to drive the growth of the overall market.
In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided USD 23 million to the Broad Institute and Harvard University, and DNA Script. The organizations are working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. Such developments are a major boost to the clinical studies and organizations progressing with NGS as their basis of innovation.
In the recent past, NGS has been considered the most potent tool in diagnostic and in researches to understand the treatment regimen for various diseases including cancer, infectious diseases, cardiovascular diseases etc. According to the United States National Institutes of Health, National Human Genome Research Institute in 2017, most of the rare diseases are genetic in nature. There has been continuous progress in the understanding of diseases at the genomic level and molecular level and various companies are deploying resources in the testing of these diseases to leverage opportunities which is also fueling the market opportunities. For instance, in August 2020, GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., and OPKO Health company entered into an agreement with Pediatrix Medical Group, to offer state-of-the-art, next-generation genomic sequencing to support clinical diagnosis in rare diseases for neonatal intensive care units. Also, earlier in 2017, Myriad Genetics, Inc. launched the EndoPredict test for patients with ER+ HER2- early-stage breast cancer.
The rapid speed, cost, and accuracy of the NGS technology have also helped in the growth of the market. However, the current market is also facing challenges, owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people, are pulling back the growth of the market.
Key Market Trends
Whole Genome Sequencing Segment is Expected to Grow at Good Rate Over the Forecast Period
By type of sequencing, whole-genome sequencing is expected to grow positively. The whole-genome sequencing (WGS) has been widely accepted in providing the highest possible resolution information about COVD-19 and is believed to have the potential to transform COVID-19 infectious disease management. For instance, in earlier 2020, the United Kingdom government launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. The COVID-19 Genomics UK Consortium (COG-UK) is comprised of the NHS (National Health Service), Public Health Agencies, the Wellcome Sanger Institute, and several academic institutions, helping in creating funds and development of diagnostics as well as treatment. In the United States, the National Institutes of Health is one of the primary organizations in the country supporting innovative studies via sequencing by growing funds for the same.
Also, there are various technological advancements in the field of whole-genome sequencing that is growing at a rapid pace which is fuelling the market growth. For instance, in February 2019, Machaon Diagnostics launched a 48-hour STAT Hemophagocytic (Lymphohistiocytosis (HLH) Genetic Panel, one of the fastest NGS genetic testing panels for Hemophagocytic Lymphohistiocytosis, a rare disease in young children and infants due to cancer. Such developments by the major players as well as their collaborations with innovative upcoming companies in sequencing and diagnostics, are propelling the growth of the whole genome sequencing segment of the market.
North America is Expected to Hold Major Share of the Market in the Forecast Period
Next-generation sequencing (NGS) technology is gaining popularity as a routine clinical diagnostic test, particularly with the pandemic of COVID-19 infection in this region. For instance, in August 2020, Helix Laboratory received United States Food and Drug Administration approval for its COVID-19 NGS test, which is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens for COVID-19 suspected individuals.
North America is expected to hold the largest market share in the NGS market. The rising focus of the major market players is on delivering advanced, efficient NGS technology to the developing countries, in order to cater to the need for genomic medicines and whole-genome sequencing for personalized medicine. For instance, in January 2018, Thermo Fisher introduced the upgraded Ion AmpliSeq Exome RDY kit that enables cost-effective, rapid identification of copy number variations, small insertions, or deletions. These advanced technologies assist in understanding heritability and complex disorders thereby favoring DNA sequencing growth in the forthcoming future. In addition, the increasing adoption of NGS technology by the non-government and government bodies, along with increased funding by the federal government and the private players, is expected to drive the market growth. The National Human Genome Research Institute has launched the National Human Genome Research Institute (NHGRI) Genome Technology Program and Advanced DNA Sequencing Technology awards. To provide funding and research support to the players to develop advanced and novel NGC technologies.
All these developments along with the rising healthcare expenditure and increasing geographic footprints of the players are the factors driving the growth of the market in this region.
Strategic mergers and acquisitions, and new product launches are the key strategies of the player in this market. Some of the developments that happened in the recent past are:
In 2019, Saphetor SA partnered with Swift Biosciences Inc. to standardize and accelerate the data interpretation solutions for next-generation sequencing panels. Further, in 2019, Qiagen launched NGS panels and liquid biopsy solutions with integrated bioinformatics to lead advances in cancer research. Also in 2019, PierianDx signed a partnership agreement with Illumina, Inc., to support cancer diagnostics and research. Each year there are several companies collaborating to benefit and provide the best output of results from new technologies into the NGS market. These developments are enabling the companies to increase their market presence and are helping them to gain a competitive advantage and propelling the market growth.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Application in the Clinical Diagnosis
4.2.2 Speed, Cost, and Accuracy to Spur the Market Growth
4.2.3 Efficient Replacement for Traditional Technologies (Microarrays)
4.2.4 Drug Discovery Applications Demanding NGS Technology
4.3 Market Restraints
4.3.1 Legal and Ethical Issues
4.3.2 Interpretation of Complex Data and Lack of Skilled Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Sequencing
5.1.1 Whole Genome Sequencing
5.1.2 Targeted Resequencing
5.1.3 Whole Exome Sequencing
5.1.4 RNA Sequencing
5.1.5 CHIP Sequencing
5.1.6 De Novo Sequencing
5.1.7 Methyl Sequencing
5.2 By Product Type
5.2.2 Reagents and Consumables
5.3 By End User
5.3.1 Hospitals and Healthcare Institutions
5.3.3 Pharmaceutical and Biotechnology Companies
5.4 By Application
5.4.1 Drug Discovery and Personalized Medicine
5.4.2 Genetic Screening
5.4.4 Agriculture and Animal Research
5.4.5 Other Applications
5.5.1 North America
22.214.171.124 United States (By Type of Sequencing, By Product Type, By End User, and By Application)
126.96.36.199 Canada (By Type of Sequencing, By Product Type, By End User, and By Application)
188.8.131.52 Mexico (By Type of Sequencing, By Product Type, By End User, and By Application)
184.108.40.206 Germany (By Type of Sequencing, By Product Type, By End User, and By Application)
220.127.116.11 United Kingdom (By Type of Sequencing, By Product Type, By End User, and By Application)
18.104.22.168 France (By Type of Sequencing, By Product Type, By End User, and By Application)
22.214.171.124 Italy (By Type of Sequencing, By Product Type, By End User, and By Application)
126.96.36.199 Spain (By Type of Sequencing, By Product Type, By End User, and By Application)
188.8.131.52 Rest of Europe (By Type of Sequencing, By Product Type, By End User, and By Application)
184.108.40.206 China (By Type of Sequencing, By Product Type, By End User, and By Application)
220.127.116.11 Japan (By Type of Sequencing, By Product Type, By End User, and By Application)
18.104.22.168 India (By Type of Sequencing, By Product Type, By End User, and By Application)
22.214.171.124 Australia (By Type of Sequencing, By Product Type, By End User, and By Application)
126.96.36.199 South Korea (By Type of Sequencing, By Product Type, By End User, and By Application)
188.8.131.52 Rest of Asia-Pacific (By Type of Sequencing, By Product Type, By End User, and By Application)
5.5.4 Middle East and Africa
184.108.40.206 GCC (By Type of Sequencing, By Product Type, By End User, and By Application)
220.127.116.11 South Africa (By Type of Sequencing, By Product Type, By End User, and By Application)
18.104.22.168 Rest of Middle East and Africa (By Type of Sequencing, By Product Type, By End User, and By Application)
5.5.5 South America
22.214.171.124 Brazil (By Type of Sequencing, By Product Type, By End User, and By Application)
126.96.36.199 Argentina (By Type of Sequencing, By Product Type, By End User, and By Application)
188.8.131.52 Rest of South America (By Type of Sequencing, By Product Type, By End User, and By Application)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 BioMerieux SA
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Charles River
6.1.5 DNASTAR Inc.
6.1.6 Eurofins Scientific
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 GATC Biotech AG
6.1.9 Genome Life Sciences
6.1.11 Illumina Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS